Pharmacovigilance and the Italian Medicines Agency
- 1*,
- 1
- 1Pharmacovigilance Unit, Italian Medicines Agency, Via del Tritone, Rome, Italy.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Giuseppe Pimpinella
Pharmacovigilance Unit, Italian Medicines Agency, Via del Tritone, Rome, Italy.
Email: g.pimpinella@aifa.gov.it
Copyright: © 2013 The Author(s). This is an open access article.
Abstract
The new European Union (EU) regulations on pharmacovigilance require that the national systems are strengthened in order to fit the new requirements. The Italian Pharmacovigilance System, coordinated by the Italian Medicines Agency (AIFA), is made by local and regional structures. In 2007, a program for funding active pharmacovigilance projects in the Italian Regions was established by the National law. The AIFA is responsible for the preparation of guidelines aimed at the identification of research areas and for the approval of the projects submitted by the regions. In April 2012, the AIFA started a program of visits at the regional pharmacovigilance centers (RPCs), aimed at monitoring their performances, evaluating the quality of the activities in order to understand the main differences and discrepancies and with a view to start a program of harmonization of the procedures in place. The outcome of the visits program highlighted major differences among the quality management systems of the various centers; hence, AIFA has decided to launch an initiative to promote in the next months the harmonization of procedures. The synergy among AIFA, regional structures, RPCs, and local structure responsible for pharmacovigilance is needed in order to establish a robust pharmacovigilance system working in full compliance with the provisions of the new EU legislation.
Keywords
Subject
Recommended articles
- Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Cohort of Patients with Type 2 Diabetes Mellitus Undergoing Phlebotomy at an Endocrinology Clinic
Nor Humaira Mohd Tajudin, Mathumalar Loganathan Fahrni, Rohana Abdul Ghani · Journal of Pharmacology and Pharmacotherapeutics
- Identification of risk factors for carbamazepine‑induced serious mucocutaneous adverse reactions: A case‑control study using data from spontaneous adverse drug reaction reports
Ilma Bertulyte, Sofie Schwan, Pär Hallberg · Journal of Pharmacology and Pharmacotherapeutics
- The safety of ketoprofen in different ages
Claudia Carbone, Pierandrea Rende, Pasquale Comberiati · Journal of Pharmacology and Pharmacotherapeutics
- Vertigo/dizziness as a Drugs’ adverse reaction
Serafina Chimirri, Rossana Aiello, Carmela Mazzitello · Journal of Pharmacology and Pharmacotherapeutics
- Informatics applied to pharmacovigilance: Future perspectives
Michele Menniti, Annamaria Menniti, Marinella Patanè · Journal of Pharmacology and Pharmacotherapeutics
- Pharmacovigilance in Asia
Pipasha Biswas · Journal of Pharmacology and Pharmacotherapeutics
Readers Also Viewed
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Knowledge, Attitude, and Practice on Digital Eye Strain Among Healthcare Students at a Private University in Northern Peninsular Malaysia
Lim Chin Hung, Subramani Parasuraman, Sam Aaseer Thamby
Jan 1, 2026